Patient characteristics
| Patient factor | N (%) |
| Gender | |
| Male | 62 (58%) |
| Female | 45 (42%) |
| WHO performance | |
| 0 | 69 (64%) |
| 1 | 30 (28%) |
| 2 | 2 (2%) |
| Unknown | 6 (6%) |
| Treatment regimen | |
| Nivolumab | 62 (58%) |
| Pembrolizumab | 45 (42%) |
| Prior systemic treatment lines | |
| 0 | 88 (82%) |
| 1 | 18 (17%) |
| 2 | 1 (1%) |
| Brain metastases | |
| Present at baseline | 18 (17%) |
| Absent at baseline | 48 (45%) |
| No screening performed | 41 (38%) |
| BOR | |
| CR | 15 (14%) |
| PR | 38 (35.5%) |
| SD | 13 (12%) |
| PD | 38 (35.5%) |
| Not evaluable | 3 (3%) |
| Continuous variables | Median (IQR) |
| Age | 66 (55–73) |
| LDH at baseline | 216 (183–306) |
BOR, best overall response; CR, complete response; LDH, lactate dehydrogenase; PD, progressive disease; PD, partial response; SD, stable disease.